|
Post by otherottawaguy on Feb 25, 2015 9:27:04 GMT -5
Did we learn anything?
I could hardly follow what MNKD was saying let alone what the question was that was being asked.
OOG
|
|
|
Post by kc on Feb 25, 2015 9:30:21 GMT -5
Very garbled call Did we learn anything?
I could hardly follow what MNKD was saying let alone what the question was that was being asked.
OOG
|
|
|
Post by whosmitchconnor on Feb 25, 2015 9:31:01 GMT -5
Me either. Turned it off after a couple minutes. According to the people with decent audio it went well though.
|
|
|
Post by bradleysbest on Feb 25, 2015 10:01:28 GMT -5
I'll wait for the transcripts.....
|
|
|
Post by ripano on Feb 25, 2015 10:20:09 GMT -5
Conference call replay on MNKD home page is very clear to listen now.
|
|
|
Post by cybergym66 on Feb 25, 2015 10:52:17 GMT -5
It was actually quite clear for me...I've listened to the past 5 CC and never had an issue...
|
|
|
Post by dallasfan on Feb 25, 2015 11:16:01 GMT -5
I listened to the replay which was good until it started to break up at the end.
Few things...
- No advertising for afrezza until 2nd half of the year. When they start it will be in journals and magazines first - they are preparing for Pediatric study trials which are about to get underway in April? Sanofi is now in charge of and responsible for all studies of course - 12 unit insulin will be produced in 2nd quarter. Matt also mentioned the lines will be producing in the 120 million cartridges range (i assume lower output than originally mentioned because of the 12 unit cartridges or possibly because of more samples or maybe he was lowballing) - sanofi is targeting general practitioners and endo. Feels this product is so easy to use that an endo is not necessary. Might be the reason for the bump in sales reps mentioned at the cafe.
Sure there was other stuff i forgot.
|
|
|
Post by dallasfan on Feb 25, 2015 11:40:21 GMT -5
Also talked about sanofi remaining milestones triggers.
- 25 million development milestone undisclosed at this point (i would guess this is related to glp) - launch in other countries - rest are sales milestones. Said one is relatively low and would be trigger relatively soon. Other milestones are in line to be triggered in conjunction with needing to build and ramp up to additional lines.
|
|
|
Post by tripoley on Feb 25, 2015 11:46:04 GMT -5
I listened to the replay which was good until it started to break up at the end. Few things... - No advertising for afrezza until 2nd half of the year. When they start it will be in journals and magazines first - they are preparing for Pediatric study trials which are about to get underway in April? Sanofi is now in charge of and responsible for all studies of course - 12 unit insulin will be produced in 2nd quarter. Matt also mentioned the lines will be producing in the 120 million cartridges range (i assume lower output than originally mentioned because of the 12 unit cartridges or possibly because of more samples or maybe he was lowballing) - sanofi is targeting general practitioners and endo. Feels this product is so easy to use that an endo is not necessary. Might be the reason for the bump in sales reps mentioned at the cafe. Sure there was other stuff i forgot. 120M cartridges a year is from the first line correct?
|
|
|
Post by dallasfan on Feb 25, 2015 12:01:05 GMT -5
Yes. He mentioned 120-121 million for first line and 400 million for 3 lines,
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 25, 2015 12:31:48 GMT -5
Yes. He mentioned 120-121 million for first line and 400 million for 3 lines, This goes in line with what we've known. 120mil for Line 1 is roughly 110,000 patients served per year assuming 1 box per month. 140mil for Line 2 is roughly 130,000 patients served per year assuming 1 box per month. 140mil for Line 3 is roughly 130,000 patients served per year assuming 1 box per month. 400mil cartridges max supporting 370,000 patients per year assuming 1 box per month. These are based on expected yields and runtimes, which are no doubt being sandbagged lower. I'd put this at around 450-500mil cartridges and 400,000 - 450,000 patients per year. Im going to go out on a limb and suggest that avg boxes per prescription will average over 1.0. For example, we know that Afrezzauser got 2 boxes with his script. You can calculate what "sold out" means in 2015, but for a full year, its about 1 to 1.2 billion in sales. (This is for 1/4th the max capacity of Danbury)
|
|
|
Post by mnholdem on Feb 25, 2015 12:36:21 GMT -5
Danbury, running at full capacity (12 lines), "will only meet a fraction of the worldwide demand" for Afrezza, according to Al Mann in a recent interview.
|
|
|
Post by dallasfan on Feb 25, 2015 12:45:19 GMT -5
Yeah i think the average user of the current 4/8 units are around 120 per month. That assuming every fourth person will use 2 boxes a month...could be higher.
i would imagine the first sales milestone will be triggered when we get above 100,000 patients. Probably 50 million for each successive 100,000 patient triggered. This would give the mnkd time to plan for the growth in the lines and also have the money to pay for the lines.
|
|
|
Post by mannmade on Feb 25, 2015 13:24:33 GMT -5
I think the next milestone payment that is sales related will be triggered by a lot less than 100,000 patients as Matt (or Hakan) said yesterday that the first sales milestone payment will be "easily" reached and soon as I recall. Now if he had the number of 100,000 patients in mind when he said that I would be very happy to know such...
|
|
|
Post by kc on Feb 25, 2015 13:45:50 GMT -5
from a STOCKTWITS poster today. I did not write them and only posting them. Not sure if it was from the RBC call or the ER call on Tuesday.
|
|